Viktor Drvota

AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. Its lead program AC01 is planned to enter phase 2 clinical development in heart failure patients in 2022. You can find more information about AnaCardio at www.anacardio.com.

OssDsign is a developer and global provider of next generation orthobiologics products. Based on cutting edge material science, the company develops and markets products that support the body's own healing capabilities, giving patients back the life they deserve. Website: www.ossdsign.com Newsroom: https://news.cision.com/ossdsign-ab (Always consult Instructions for Use which accompany the products for complete indications, contraindications, warnings and precautions.)

AVIDICARE AB Avidicare AB is a research based medtech company with a unique technology for management of airborne bacteria and virus contamination in hospitals. Opragon® is the company’s major product and Opragon is a complete product line for reduction of airborne bacterial contamination in hospitals, primarily for infection sensitive surgery. Ensuring ultra-clean air in the whole operating room, Opragon also provides optimal working conditions for the operating team while saving energy. Its state-of-the art design enables flexible installations and shows how we help healthcare providers work Towards Zero Infections.

Neoventa provides innovative fetal monitoring solutions and services that improve obstetric care. Our solutions are designed to promote patient safety through enhanced decision support together with a structured workflow. Every day across the globe, health care professionals use our unique solutions to ensure a good start in life. Our core competence lies in using the Stan fetal & maternal monitor to perform evidence-based ST Analysis of the fetal ECG as an adjunct to CTG, “a second pair of eyes” during childbirth. We are also the provider of disposable fetal spiral electrodes for internal fetal monitoring under the brand Goldtrace. Another important area of business is a comprehensive education and training program, Neoventa Academy, which includes e-learning with certification.

InDex Pharmaceuticals in brief InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is being evaluated in the phase III study CONCLUDE as a novel treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases. InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm.

AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. Its lead program AC01 is planned to enter phase 2 clinical development in heart failure patients in 2022. You can find more information about AnaCardio at www.anacardio.com.

Karolinska Development AB is an investment company focused on identifying medical innovation and investing in the creation and growth of companies developing these assets into differentiated products that will make a difference to patients’ lives and provide an attractive return on investment. Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success. Karolinska Development has established a portfolio of 10 companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases. The Company is led by a team including investment professionals with strong venture capital backgrounds, experienced company builders and entrepreneurs, with access to a strong global network. For more information, please visit www.karolinskadevelopment.com